

# Marijuana Use Impacts Midlife Cardiovascular Events in HIV-Infected Men

David R. Lorenz,<sup>1</sup> Anupriya Dutta,<sup>1</sup> Shibani S. Mukerji,<sup>1,2</sup> Alex Holman,<sup>1</sup> Hajime Uno,<sup>3</sup> and Dana Gabuzda<sup>1</sup>

<sup>1</sup>Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, <sup>2</sup>Department of Neurology, Massachusetts General Hospital, and <sup>3</sup>Department of Population Science, Dana-Farber Cancer Institute, Boston, Massachusetts

**Background.** Marijuana use is prevalent among persons infected with human immunodeficiency virus (HIV), but its long-term effects on HIV disease progression and comorbidities are unknown.

**Methods.** In this prospective study of 558 HIV-infected men enrolled in the Multicenter AIDS Cohort Study between 1990 and 2010, there were 182 HIV seroconverters and 376 with viral suppression on combination antiretroviral therapy (ART). Associations between heavy marijuana use and HIV disease markers or white blood cell (WBC) count were examined using mixed-effects and linear regression models. Effects of marijuana use on cardiovascular (CV) events and other endpoints were estimated using Kaplan-Meier and logistic regression analyses.

**Results.** The median baseline age of participants was 41, 66% were white, 79% had education >12 years, and 20% reported heavy marijuana use at ≥50% of biannual visits during follow-up. Long-term heavy marijuana use showed no significant associations with viral load, CD4 counts, AIDS, cancer, or mortality in both cohorts but was independently associated with increased CV events between ages 40–60 after adjusting for age, tobacco smoking, viral load, and traditional risk factors (odds ratio [OR], 2.5; 95% confidence interval [CI] 1.3, 5.1). Marijuana and tobacco use were each independently associated with higher WBC counts in adjusted models ( $P < .01$ ); the highest quartile of WBC counts (≥6500 cells/μL) was associated with increased CV events (OR 4.3; 95% CI, 1.5, 12.9).

**Conclusions.** Heavy marijuana use is a risk factor for CV disease in HIV-infected men ages 40–60, independent of tobacco smoking and traditional risk factors.

**Keywords.** HIV; AIDS; marijuana; cardiovascular disease.

Marijuana use for recreational and medicinal purposes is prevalent among individuals infected with human immunodeficiency virus type 1 (HIV). Recent estimates in cohorts of HIV-infected (HIV+) men who have sex with men (MSM) range from 24% to 62% [1–3]. Despite this high prevalence, few studies have investigated health effects of long-term heavy marijuana use among HIV+ individuals [4]. Observational studies reported contradictory findings regarding associations between marijuana use and HIV viral load [5–9] or CD4 cell counts [1, 3, 5, 6, 10]. Animal model studies also report inconsistent effects of tetrahydrocannabinol administration on viral

replication and disease progression [11, 12]. Thus, the effects of marijuana use on HIV disease and associated comorbidities remain unclear.

Cardiovascular (CV) disease is a comorbidity of particular concern in HIV+ populations [13], given that the estimated incidence is up to 2-fold higher than that of age-matched uninfected controls [14, 15]. The high prevalence of tobacco smoking and other traditional CV risk factors, combination antiretroviral therapy (ART)-associated dyslipidemia, and healthcare disparities explain only a portion of this elevated risk [16–21]. Thus, identifying nontraditional risk factors that explain elevated CV risk in HIV-infected populations is a priority for improving health outcomes [13–15]. Marijuana smoking has been associated with myocardial infarction and other adverse CV events in a few studies of HIV-uninfected individuals [22–25], yet the evidence regarding its effects on CV disease remains unclear [4]. To our knowledge, its effects on CV disease in HIV+ individuals have been evaluated in only 1 study [20].

Our aims in this longitudinal study were to examine the effect of long-term heavy marijuana use on HIV disease markers in men with acute and chronic HIV infection and to evaluate

Received 12 January 2017; editorial decision 13 April 2017; accepted 21 April 2017; published online April 25, 2017.

Correspondence: D. Gabuzda, Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Center for Life Science 1010, 450 Brookline Avenue, Boston, MA 02215 (dana\_gabuzda@dfci.harvard.edu).

**Clinical Infectious Diseases**® 2017;65(4):626–35

© The Author 2017. Published by Oxford University Press for the Infectious Diseases Society of America. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (<http://creativecommons.org/licenses/by-nc-nd/4.0/>), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact [journals.permissions@oup.com](mailto:journals.permissions@oup.com) DOI: 10.1093/cid/cix391

differences in CV events and other health outcomes during long-term follow-up.

## METHODS

### Study Cohort


The Multicenter AIDS Cohort Study (MACS) is an ongoing prospective study of HIV-infected and HIV-uninfected MSM [26, 27]. Participants undergo standardized interviews detailing behavioral characteristics, medical treatments or conditions, physical examinations, and collection of biological specimens at biannual study visits. All participants provided written informed consent, and each site's institutional review board approved the study protocols.

In this study we examined 2 independent cohorts from the MACS public data release P23 using visits from 1990 through 2010 (Figure 1A): HIV-negative (HIV-) participants who seroconverted after MACS enrollment (HIV seroconverters)

and HIV+ participants with baseline viral suppression on combination ART (chronic HIV). Inclusion criteria for HIV seroconverters were first HIV antibody positive visit after 1990; baseline was anchored to midpoint between last documented HIV- (1989 or later) and first HIV+ visit. Inclusion criteria for those with chronic HIV were a baseline visit in 1996 or later with at least 1 year of prior combination ART use and baseline viral load <400 HIV RNA copies/mL and CD4 cell count  $\geq 300$  cells/ $\mu$ L. Hepatitis C virus (HCV) antibody-positive patients and those reporting 1 year or more of other heavy drug use (daily nitrite inhalants [poppers] or uppers use, daily or weekly cocaine or heroin use) were excluded from the study.

### Exposure Variables

Marijuana was the primary exposure of interest. Participants were classified based on self-reported frequency of marijuana



**Figure 1.** Cohort selection and longitudinal patterns of marijuana and smoking exposures. *A*, Cohort selection flowchart. *B*, Lasagna plots illustrating self-reported patterns of marijuana use (top panel) and cigarette smoking (bottom panel) among participants in the chronic HIV cohort. Each row depicts visit-level exposure data for an individual in the study interval used for group classification. Abbreviations: cART, combination antiretroviral therapy; HCV, hepatitis C virus; HIV, human immunodeficiency virus.

use as heavy users (defined as daily or weekly use at  $\geq 50\%$  of biannual visits), nonusers (less than monthly or no use at all visits), and occasional users (remaining participants). Participants who reported smoking an average of 0.25 cigarette packs/day or more were classified as moderate/heavy tobacco smokers.

### Outcome and Covariate Definitions

HIV disease markers included plasma viral load, CD4+ and CD8+ T lymphocyte cell counts, and CD4:CD8 ratio [20]. White blood cell (WBC) counts were examined given prior association with cigarette smoking and marijuana use [28, 29]. Ascertainment of health outcomes in the MACS, including AIDS, cancer, and CV diagnoses, has been described elsewhere [19, 27, 30, 31]. Study endpoints for each participant were defined as follows: first incident event after age 30 for AIDS diagnoses, cancer, and mortality; first incident event after age 40 for CV events; loss to follow-up, last visit in 2010, or age 60. These age ranges were selected based on the known association of age  $\geq 40$  with CV risk and limited follow-up or events before age 30 and after age 60. AIDS diagnoses included participants with CD4 counts  $< 200$  cells/ $\mu\text{L}$  during follow-up. Cancer diagnoses were classified using International Classification of Diseases for Oncology, third edition (ICD-O-3), codes [31]. A CV composite endpoint was comprised of the following ICD-ninth edition, codes [16]: myocardial infarction (410), ischemic heart disease (411, 414, 429.2), angina pectoris (413), cerebrovascular disease (433, 434, 435), atherosclerosis (440), and heart failure (428). Traditional CV risk factors (diabetes mellitus, hypertension, and hypercholesterolemia) were defined based on reported use of medications for these conditions for 1 year or more during 10 years prior to endpoint or based on mean laboratory test values at the 2 most recent visits prior to endpoint within 5 years: diabetes, hemoglobin A1C  $\geq 6.5\%$ ; hypertension, systolic blood pressure  $> 140$  or diastolic blood pressure  $> 90$ ; and hypercholesterolemia, total cholesterol  $> 240$ .

### Statistical Methods

Mixed-effects models were fit for each time-varying HIV disease marker as a continuous dependent variable. Marijuana use, smoking, age at baseline, race, and education were time-invariant categorical covariates. Duration in study was a time-varying covariate. Additional models for time-varying WBC and neutrophil count fit for the merged HIV+ cohort with follow-up between ages 40 and 60 included viral load and total cholesterol as time-varying categorical covariates. All models included a random intercept and slope.

Stratified Kaplan-Meier curves were used to assess differences in mortality and health outcomes in the merged HIV+ cohort by marijuana use or smoking, with age as the time axis and allowing staggered entry. Individuals with events prior to entry age were excluded from analyses; log-rank test was used to evaluate statistical significance of differences between groups.

Case-control data at endpoint was used to assess associations between marijuana use, CV events, and WBC count in the merged HIV+ cohort with follow-up between ages 40 and 60. Logistic and linear regression models were fit with CV event and time-updated  $\log_2$ -transformed WBC count, respectively, as dependent variables. Predictors included time-updated marijuana use, tobacco smoking, age, race, HIV viral load, and traditional risk factors; linear regression models also included total cholesterol. All analyses were performed using R, version 3.2.

## RESULTS

### Clinical Characteristics

A total of 558 individuals met eligibility requirements for the HIV seroconverter ( $n = 182$ ) and chronic HIV ( $n = 376$ ) cohorts, respectively; heavy marijuana users comprised approximately 20% of both cohorts (Figure 1A). Participants were predominantly white, with  $> 12$  years of education, median age 40.8 years at baseline, and median duration between last HIV- and first HIV+ visit 1.0 years for HIV seroconverters (Table 1). Heavy marijuana use was associated with cigarette smoking in both cohorts ( $P = .035$  and  $P = < .001$ ). There were no significant associations between heavy marijuana use and other demographic and baseline characteristics, including age, race, education, alcohol use, Center for Epidemiological Studies Depression Scale (CES-D) depression scores, viral load, and CD4 count. Self-reported ART use, adherence, and regimens were similar between marijuana users and nonusers (Table 1 and Supplementary Table 1). The patterns of both marijuana and tobacco use remained generally consistent over time within individual participants (Figure 1B).

An all-by-all comparison of baseline and demographic characteristics stratified by marijuana use (Supplementary Figure 1) indicated more cigarette smoking among heavy marijuana or alcohol users, yet no other associations were observed. CES-D depression scores were lower with increasing age, yet these trends did not vary by marijuana use.

### Marijuana Use and HIV-Related Outcomes

Marijuana use showed no significant association with mean trajectories of HIV disease markers, including no dose-response relationship when stratifying by daily vs weekly use (Figure 2A). In mixed-effects models adjusted for age, smoking, race, and education, daily marijuana use was associated with lower CD4:CD8 ratio at baseline in the chronic HIV cohort ( $P = .009$ ; Supplementary Table 2), but this effect was not reproduced in HIV seroconverters ( $P = .457$ ). There was no significant association between daily or weekly use and other HIV disease markers.

Next, we evaluated associations between marijuana use and HIV-related outcomes during long-term follow-up. There were no significant associations between heavy marijuana

**Table 1. Baseline and Updated Cohort Characteristics**

Characteristic	HIV Seroconverters			PValue <sup>a</sup>	Chronic HIV			PValue <sup>a</sup>
	Nonusers (n = 102)	Heavy Marijuana (n = 36)	Occasional Marijuana (n = 44)		Nonusers (n = 244)	Heavy Marijuana (n = 65)	Occasional Marijuana (n = 67)	
Length of follow-up, mean (standard deviation), y	7.7 (2.6)	7.5 (2.3)	7.9 (2.1)	.715	5.5 (2.1)	5.1 (2.1)	5.82 (1.9)	.157
Seroconversion window, median (IQR), y <sup>b</sup>	1.0 (0.0–1.0)	1.0 (0.0–1.0)	1.0 (0.0–1.0)	.500	—	—	—	—
Age, median (IQR), y	40.5 (33–47)	33.3 (28–42)	37.8 (32–41)	.015	42 (37–46)	41 (35–49)	41.5 (36–47)	.771
Racial/ethnic group				.161				.411
White	83 (81.4)	23 (63.9)	36 (81.8)		146 (59.8)	33 (50.8)	42 (62.7)	
Black	12 (11.8)	9 (25.0)	7 (15.9)		55 (22.5)	21 (32.3)	17 (25.4)	
Other	7 (6.9)	4 (11.1)	1 (2.3)		43 (17.6)	11 (16.9)	8 (11.9)	
Education >12 years	86 (84.3)	32 (88.9)	38 (86.4)	.789	187 (76.6)	49 (75.4)	50 (74.6)	.934
Heavy or binge alcohol use <sup>c</sup>	26 (25.5)	13 (36.1)	12 (27.3)	.471	54 (22.1)	17 (26.2)	22 (32.8)	.19
Moderate/heavy cigarette smoking <sup>d</sup>	27 (26.5)	18 (50.0)	15 (34.1)	.035	60 (24.6)	35 (53.8)	27 (40.3)	<.001
CES-D score, median (IQR)	9 (4–16)	9 (3–16)	13 (2–20)	.981	8 (3–16)	7.5 (5–16)	13 (7–20)	.023
CES-D score ≥16	26 (26.3)	11 (30.6)	14 (34.1)	.628	63 (26.2)	18 (28.1)	26 (40.6)	.078
CD4 count (cells/μL), median (IQR)	629 (455–855)	667 (507–834)	680 (544–828)	.552	559 (445–741)	548 (432–620)	553 (435–790)	.312
HIV viral load ≥400 copies/mL	78 (89.7)	30 (93.8)	30 (88.2)	.728	0 (0.0)	0 (0.0)	0 (0.0)	—
Any ART use in study period <sup>e</sup>	82 (80.4)	29 (80.6)	33 (75)	.742	244 (100)	65 (100)	67 (100)	—
ART adherence at ≥95% of visits <sup>e</sup>	75 (91.5)	27 (93.1)	25 (75.8)	.04	167 (68.4)	43 (66.15)	41 (61.2)	.533
AIDS diagnoses <sup>f</sup>	32 (31.4)	8 (22.2)	17 (38.6)	.344	16 (6.6)	6 (9.2)	4 (6.0)	.690
Mortalities <sup>f</sup>	20 (19.6)	6 (16.6)	10 (22.7)	.794	9 (3.7)	3 (4.6)	3 (4.5)	.794
One or more cancer diagnoses <sup>f</sup>	14 (13.7)	3 (8.3)	7 (15.9)	.634	13 (5.3)	4 (6.0)	3 (4.5)	.891
One or more cardiovascular events <sup>f</sup>	8 (11.1)	3 (14.3)	1 (2.9)	.311	13 (6.7)	14 (29.2)	5 (10.9)	<.001

Data are n (%) at baseline visit (index date of the analysis) unless otherwise specified. Study period for seroconverter and chronic HIV cohorts: –4 years to +7 years relative to baseline and baseline to +7 years, respectively.

Abbreviations: ART, antiretroviral therapy; CES-D, Center for Epidemiological Studies Depression Scale; HIV, human immunodeficiency virus; IQR, interquartile range.

<sup>a</sup>χ<sup>2</sup> or Fisher exact test, analysis of variance, or Kruskal-Wallis rank sum test for categorical, normally distributed continuous, and nonnormally distributed continuous variables, respectively.

<sup>b</sup>Duration between last HIV– and first HIV+ visits.

<sup>c</sup>Heaviest reported usage at ≥2 visits in study period: heavy, >14 drinks/week; binge, 5 or more drinks/occasion at least monthly.

<sup>d</sup>Average ≥0.25 packs/day during study period.

<sup>e</sup>Self-reported current ART medication use.


<sup>f</sup>Incident events during post-baseline follow-up, restricted to ages 40–60 years for cardiovascular events.

use and progression to AIDS, cancer diagnoses, or mortality in either cohort (Table 1). AIDS-related causes of death comprised 68.1% of all mortalities; the AIDS-defining malignancies (ADMs) Kaposi sarcoma (32.8%) and non-Hodgkin lymphoma (20.7%) comprised the majority of cancer diagnoses. By contrast, a higher proportion of heavy marijuana users had CV events between ages 40 and 60 years compared with non- and occasional users in both cohorts ( $P = .311$  and  $P < .001$ ; Table 1). Consistent with these findings, Kaplan-Meier curves for the merged HIV+ cohort between ages 40 and 60 showed elevated rates of incident CV events among heavy marijuana users ( $P < .001$ ; Figure 2B), while there was no significant difference in rates of AIDS diagnoses, cancer, or mortality (Figure 2B).

#### Marijuana Use, Increased WBC Count, and Cardiovascular Events

Previous studies demonstrated significant associations between tobacco smoking, elevated WBC count, and coronary heart disease [28, 29, 32], but these associations have not been

explored in the context of marijuana use during HIV infection. We therefore evaluated mean trajectories of WBC counts stratified by marijuana and tobacco use over the first 6 years of follow-up in both cohorts. Mean WBC counts were elevated in cigarette smokers vs nonsmokers; the highest mean WBC counts were observed in marijuana/tobacco co-users in both cohorts (Supplementary Figure 2). In mixed-effects models adjusted for age, race, education, viral load, and total cholesterol, cigarette smoking was associated with higher WBC count (estimate = .153;  $P < .0001$ ), and heavy marijuana use was associated with increasing WBC count in the merged HIV+ cohort between ages 40 and 60 (marijuana × age interaction: estimate = .020;  $P < .001$ ; Figure 3A and Supplementary Table 3). Comparable estimates were observed for neutrophil counts (Figure 3A and Supplementary Table 3), but not monocyte or lymphocyte counts, in models adjusted for the same covariates. Thus, neutrophils are the main leukocyte population explaining higher WBC counts. Using case-control data at endpoint, heavy marijuana use (estimate = 1.11;  $P = .01$ )




**Figure 2.** Association between marijuana use, HIV disease marker trajectories, and health outcomes. *A*, Mean values of HIV disease markers by marijuana use. *B*, Kaplan-Meier curves of AIDS diagnoses, mortality, cancer diagnoses, and cardiovascular events for the merged HIV+ cohort stratified by marijuana use. *P* values denote pair-wise log-rank test vs control group. Abbreviations: HIV, human immunodeficiency virus.

and cigarette smoking (estimate = 1.15;  $P < .0001$ ) were each independently associated with increased WBC count in linear regression models (Table 2). The interaction between marijuana use and smoking was not significant in mixed-effects and linear regression models, providing further evidence for independent effects of these factors.

Given the high prevalence of cigarette smoking among marijuana users, we evaluated associations between marijuana use, cigarette smoking, and CV event rates in the merged HIV+ cohort between ages 40 and 60. CV events occurred in 19.7% of heavy marijuana users compared with 8.7% of occasional and nonusers ( $P = .012$ ), while demographics and HIV disease characteristics were similar at endpoint (Supplementary Table 4). Kaplan-Meier curves showed increased CV and non-AIDS-defining malignancy rates among cigarette smokers ( $P < .001$  and  $P < .05$ ; Figure 3B, left panel, and Supplementary Figure 3), while there was no significant effect on progression to AIDS, mortality, or ADM diagnoses (Supplementary Figure 3). CV event rates were also increased among marijuana users who did not smoke cigarettes compared with nonsmokers and were highest among marijuana/tobacco co-users ( $P < .01$  and  $P < .001$ ; Figure 3B, right panel). Among cigarette smokers, average cigarette packs/day was similar between marijuana users and nonusers

(mean 0.88 vs 0.96 packs/day, respectively;  $P > .3$ , *t* test), indicating Kaplan-Meier estimates were not influenced by more cigarette smoking among marijuana/tobacco co-users. In logistic regression models adjusted for age, smoking, viral load, and 2–3 vs 0–1 traditional CV risk factors, time-updated heavy marijuana use was associated with 2.5-fold increased odds of CV events (95% confidence interval [CI], 1.2–5.3;  $P = .016$ ). Effects of marijuana/tobacco co-use on increased odds of CV events were additive in this model (odds ratio, 4.8 [95% CI, 1.8–12.7];  $P < .01$ ; Table 3). The association between heavy marijuana use and CV risk was not modified by detectable HIV viral load (estimate for interaction = 0.740;  $P = .358$ ). Other risk factors were not significantly associated with increased odds of CV events, except for diabetes and elevated platelet count (Supplementary Table 5), which were not significant in adjusted models. Similar to results in logistic regression models, time-varying heavy marijuana use was associated with increased incident CV events in Cox proportional hazard models adjusted for time-varying cigarette smoking, viral load, and traditional risk factors (hazard ratio, 2.16; 95% CI, 1.04–4.51;  $P = .039$ ).

In a separate multivariate logistic regression model, higher WBC count was associated with increased odds of CV events (Table 3 and Figure 3C). Time-updated WBC count in the



**Figure 3.** Heavy marijuana use and white blood cell (WBC) count are independently associated with increased odds of cardiovascular (CV) events. *A*, Estimated mean trajectories for WBC (top panels) and neutrophil counts (bottom panels) by cigarette smoking (left panel) or by marijuana use and cigarette smoking (right panel), for the merged HIV+ cohort with follow-up between ages 40 and 60 years from mixed effects models adjusted for viral load, race, age at entry, education, and total cholesterol (Supplementary Table 3). *B*, Kaplan-Meier curves of first CV event stratified by smoking only (left panel) or by marijuana use and cigarette smoking (right panel) for the merged HIV+ cohort with follow-up between ages 40 and 60. Mj+ denotes heavy marijuana users, Mj-, occasional or nonusers, Sm+, moderate or heavy smokers ( $\geq 0.25$  packs/day, average), Sm-, light or nonsmokers,  $P$  values, pair-wise log-rank test vs control group. *C*, Forest plot showing estimated odds of adverse CV events for the indicated covariates from logistic regression model 2 (Table 3) with WBC values by quartiles. Abbreviations: CI, confidence interval; HIV, human immunodeficiency virus; Mj, marijuana; Sm, smoking; WBC, white blood cells.

highest quartile ( $\geq 6500$  cells/ $\mu$ L) was associated with 4.3-fold increased odds of a CV event compared with the lowest quartile ( $< 4500$  cells/ $\mu$ L; 95% CI, 1.45-12.89;  $P = .009$ ). When

modeled as a continuous covariate, each 1000-cells/ $\mu$ L WBC increment was associated with 25% increased odds of a CV event independent of marijuana use, cigarette smoking, age,

**Table 2. Factors Associated With Increased White Blood Cell Count**

Predictor	Unadjusted Models		Adjusted Model	
	Estimate (95% CI)	PValue	Estimate (95% CI)	PValue
Heavy marijuana use <sup>a</sup>	1.09 (1.01, 1.18)	.023	1.10 (1.02, 1.19)	.012
Moderate/heavy cigarette smoking <sup>b</sup>	1.12 (1.05, 1.19)	<.0001	1.15 (1.08, 1.22)	<.0001
Age 45–60 vs 40–44	1.05 (0.98, 1.13)	.152	1.05 (0.98, 1.13)	.172
Race				
White	1.00 (Ref.)	—	1.00 (Ref.)	—
Black	0.86 (0.80, 0.92)	<.0001	0.87 (0.81, 0.94)	<.001
Other	0.96 (0.88, 1.05)	.331	0.97 (0.89, 1.05)	.425
Diabetes risk factor <sup>c</sup>	1.03 (0.91, 1.16)	.677	—	—
Hypertension risk factor <sup>d</sup>	1.04 (0.98, 1.11)	.179	—	—
Total cholesterol (mg/dL)				
<180	1.00 (Ref.)	—	1.00 (Ref.)	—
180–229	1.13 (1.06, 1.21)	<.001	1.11 (1.04, 1.18)	.002
≥230	1.11 (1.01, 1.21)	.023	1.10 (1.01, 1.20)	.022
HIV viral load ≥400 copies/mL	0.88 (0.82, 0.96)	.002	0.90 (0.83, 0.97)	.006

Models were fit using linear regression with time-updated log<sub>e</sub>-transformed white blood cell count (cells/μL) as the dependent variable, from the merged HIV+ cohort at first incident cardiovascular event after age 40, loss to follow-up, last visit in 2010, or age 60. All laboratory test values were the mean of the 2 most recent visits prior to endpoint.

Abbreviations: CI, confidence interval; HIV, human immunodeficiency virus.

<sup>a</sup>Daily or weekly marijuana use at ≥50% of visits in period 10 years prior to endpoint.

<sup>b</sup>Average ≥0.25 packs/day in period 10 years prior to endpoint.

<sup>c</sup>Hemoglobin A1C ≥6.5% or use of diabetes medications for at least 1 year in the 10 years prior to endpoint.

<sup>d</sup>Systolic blood pressure >140 or diastolic blood pressure >90, or use of antihypertensive medications for at least 1 year in the 10 years prior to endpoint.

**Table 3. Association Between Marijuana Use, White Blood Cell Count, and Cardiovascular Events**

Predictor	Cardiovascular Events		Unadjusted Models		Adjusted Model 1		Adjusted Model 2	
	Controls (n = 370), n (%)	Cases (n = 44), n (%)	OR (95% CI)	PValue	OR (95% CI)	PValue	OR (95% CI)	PValue
Marijuana use								
None/occasional	313 (84.6)	30 (68.2)	1.00 (Ref.)	—	1.00 (Ref.)	—	1.00 (Ref.)	—
Heavy <sup>a</sup>	57 (15.4)	14 (31.8)	2.56 (1.28, 5.13)	.008	2.51 (1.18, 5.31)	.016	2.31 (1.08, 4.93)	.031
Cigarette smoking								
None/light	261 (70.5)	21 (47.7)	1.00 (Ref.)	—	1.00 (Ref.)	—	1.00 (Ref.)	—
Moderate/heavy <sup>b</sup>	109 (29.5)	23 (52.3)	2.62 (1.39, 4.94)	.007	2.55 (1.29, 5.04)	.007	2.06 (1.01, 4.17)	.045
Age								
40–44	86 (23.2)	5 (11.4)	1.00 (Ref.)	—	1.00 (Ref.)	—	1.00 (Ref.)	—
45–60	284 (76.8)	39 (88.6)	2.36 (0.9, 6.18)	.080	3.35 (1.18, 9.57)	.024	3.10 (1.06, 9.05)	.039
Traditional risk factors <sup>c</sup>								
0–1	295 (79.7)	29 (65.9)	1.00 (Ref.)	—	1.00 (Ref.)	—	1.00 (Ref.)	—
2–3	75 (20.3)	15 (34.1)	2.03 (1.04, 3.99)	.039	2.59 (1.23, 5.43)	.012	2.44 (1.15, 5.18)	.020
HIV viral load (copies/mL)								
<400	311 (84.1)	27 (61.4)	1.00 (Ref.)	—	1.00 (Ref.)	—	1.00 (Ref.)	—
≥400	59 (16.0)	17 (38.6)	3.32 (1.70, 6.47)	<.001	3.73 (1.80, 7.72)	<.001	4.83 (2.23, 10.48)	<.001
WBC count—quartiles (cells/μL)								
<4500	93 (25.1)	5 (11.4)	1.00 (Ref.)	—	—	—	1.00 (Ref.)	—
4500–5499	108 (29.2)	9 (20.4)	1.55 (0.5, 4.79)	.445	—	—	1.69 (0.51, 5.66)	.390
5500–6499	73 (19.7)	8 (18.2)	2.04 (0.64, 6.49)	.228	—	—	2.67 (0.77, 9.20)	.120
≥6500	96 (26.0)	22 (50.0)	4.26 (1.55, 11.73)	.005	—	—	4.32 (1.45, 12.89)	.009

Time-updated values from the merged HIV+ cohort at first incident cardiovascular event after age 40, loss to follow-up, last visit in 2010, or age 60. Models were fit using logistic regression.

Abbreviations: CI, confidence interval; HIV, human immunodeficiency virus; OR, odds ratio; WBC, white blood cell.

<sup>a</sup>Daily or weekly marijuana use at ≥50% of visits in period 10 years prior to endpoint.

<sup>b</sup>Average ≥0.25 packs/day in period 10 years prior to endpoint.

<sup>c</sup>Number of cholesterol, diabetes, or hypertensive risk factors (see Materials and Methods).

viral load, and traditional risk factors (95% CI, 1.05–1.49;  $P = .012$ ); including WBC count as a covariate significantly improved model fit ( $P = .013$ , likelihood-ratio test).

## DISCUSSION

In this longitudinal nested study of HIV+ men on ART, heavy marijuana use was associated with increased rates of CV events in men aged 40–60 independent of cigarette smoking and other known risk factors. Heavy marijuana use was also associated with elevated WBC count within the normal physiological range, an indicator of systemic inflammation that has been previously associated with increased CV disease in the general population [32, 33]. Furthermore, this elevation in WBC counts was explained by increased neutrophil counts. Elevated rates of CV events were observed among HIV+ heavy marijuana users beginning at relatively young ages (<50 years) and were further increased in marijuana/tobacco co-users compared with users of only 1 substance. Further studies are needed to determine whether the effect of long-term heavy marijuana use on CV events is related to proinflammatory effects of nontobacco smoke exposure, noninflammatory effects (eg, transient tachycardia and/or hypertension, elevated carboxyhemoglobin, hemodynamic effects, effects on platelets) [22–24], or a combination of these effects.

In healthy individuals, relatively few physical health outcomes have been clearly linked to marijuana use [4, 34–36]. However, adverse CV and cerebrovascular effects of recent marijuana use have been reported in some studies of the general population [4, 22–25]. The association between long-term heavy marijuana use and increased CV event rates has not been previously reported in HIV+ individuals. A study examining associations between substance use and coronary plaque measures in the MACS reported no strong effect of marijuana [20]. However, the study design was different from ours in several respects including the narrower definition of CV disease and less stringent criteria for defining marijuana exposure. Furthermore, we excluded HCV+ individuals and other heavy illicit drug users from our study cohort. The association between marijuana use and CV events we detected was weaker than that of other known CV risk factors including age, cigarette smoking, and viral load >400 copies/mL [14, 15, 17–19, 37]. In contrast to some prior studies [14, 15, 18, 19], we found weak or no significant associations between CV events and hypertension or cholesterol risk factors, which may reflect the younger age and high smoking prevalence in our study cohort.

The association we found between heavy marijuana use and elevated WBC has been reported in healthy young men [28], but to our knowledge has not previously been reported in HIV+ individuals. In line with previous studies of HIV-uninfected populations [28, 29, 32, 33], cigarette smoking was associated with elevated WBC count in our cohort of mostly middle-aged HIV+ men. The mechanism by which marijuana exposure increases WBC count remains poorly defined but may

be related to toxic or proinflammatory effects of smoke combustion products [36, 38].

The lack of association between marijuana use and HIV disease markers, progression to AIDS, mortality, or cancer reported here is consistent with prior observational [1, 3, 6, 8, 39] and case-control [5] studies. However, other studies reported associations between marijuana use and higher CD4 counts and/or lower viral load [9], higher CD4 counts [10], and slightly lower viral loads during the first year post-seroconversion [7]. While differences between these studies likely reflect differences in study populations, selection criteria, adjustment for confounders, and length of follow-up, the results reported here are consistent with those from other studies in MSM cohorts [1, 3, 6].

Strengths of this study include more selective inclusion and exclusion criteria compared with most previous studies. The chronic HIV cohort had controlled disease characteristics at baseline (CD4 count >300 cells/ $\mu$ L, viral load <400 copies/mL), and individuals with heavy use of other illicit drugs and HCV coinfection were excluded. These factors have substantial effects on HIV disease markers and other outcomes and therefore could confound efforts to detect effects of marijuana exposure. A further strength was the classification of long-term heavy marijuana use over years of follow-up and strict criteria for classifying heavy and nonusing participants over this time span.

Limitations of this study include those inherent to studies of longitudinal cohorts, including the possibility that results may be specific to the MSM population recruited for the MACS and nonrandom ascertainment and dropout biases. Available measures of marijuana exposure were self-reported frequency of use with no information regarding route of administration, source, quantity, and potency. Based on available knowledge, the predominant mode of exposure was likely via marijuana smoking. These concerns are mitigated in part by the evaluation of 2 independent cohorts selected from differing calendar periods, which nonetheless show a consistent lack of association between marijuana use and HIV disease markers. Furthermore, we assessed CV events using time-updated data for marijuana and tobacco exposure during 10 years prior to endpoint.

In summary, we found no significant association between marijuana use and HIV disease progression or mortality. However, long-term heavy marijuana use was associated with increased midlife CV events in HIV+ men, independent of cigarette smoking and traditional risk factors. Furthermore, the increase in CV events was additive in marijuana/tobacco co-users. These findings suggest that clinicians should consider heavy marijuana smoking as a modifiable risk factor when optimizing preventive care, particularly for individuals already at increased risk. In recent years, the prevalence of cigarette smoking has declined, while the prevalence of heavy marijuana use has remained high or increased in HIV-infected populations [3, 10, 40]. Given that traditional factors are not sufficient to explain elevated CV risk among HIV+ individuals [13, 15, 22],

the identification of heavy marijuana smoking as a nontraditional risk factor helps to explain a portion of this elevated risk and warrants further investigation in other HIV-infected and uninfected populations.

### Supplementary Data

Supplementary materials are available at *Clinical Infectious Diseases* online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.

### Notes

**Acknowledgments.** The data for this manuscript were obtained by the Multicenter AIDS Cohort Study (MACS) with centers at Baltimore (U01-AI35042): Johns Hopkins University Bloomberg School of Public Health: Joseph B. Margolick (principal investigator [PI]), Jay Bream, Todd Brown, Barbara Crain, Adrian Dobs, Richard Elion, Richard Elion, Michelle Estrella, Lisette Johnson-Hill, Sean Leng, Anne Monroe, Cynthia Munro, Michael W. Plankey, Wendy Post, Ned Sacktor, Jennifer Schrack, Chloe Thio; Chicago (U01-AI35039): Feinberg School of Medicine, Northwestern University, and Cook County Bureau of Health Services: Steven M. Wolinsky (PI), John P. Phair, Sheila Badri, Dana Gabuzda, David Ostrow, Frank J. Palella, Jr, Sudhir Penugonda, Susheel Reddy, Matthew Stephens, Linda Teplin; Los Angeles (U01-AI35040): University of California, UCLA Schools of Public Health and Medicine: Roger Detels (PI), Otoniel Martínez-Maza (co-PI), Aaron Aronow, Peter Anton, Robert Bolan, Elizabeth Breen, Anthony Butch, Shehnaaz Hussain, Beth Jamieson, Eric N. Miller, John Oishi, Harry Vinters, Dorothy Wiley, Mallory Witt, Otto Yang, Stephen Young, Zuo Feng Zhang; Pittsburgh (U01-AI35041): University of Pittsburgh, Graduate School of Public Health: Charles R. Rinaldo (PI), Lawrence A. Kingsley (co-PI), James T. Becker, Phalguni Gupta, Kenneth Ho, Susan Koletar, Jeremy J. Martinson, John W. Mellors, Anthony J. Silvestre, Ronald D. Stall; Data Coordinating Center (UM1-AI35043): Johns Hopkins University Bloomberg School of Public Health: Lisa P. Jacobson (PI), Gypsyamber D'Souza (co-PI), Alison, Abraham, Keri Althoff, Jennifer Deal, Priya Duggal, Sabina Haberlen, Alvaro Muoz, Derek Ng, Janet Schollenberger, Eric C. Seaberg, Sol Su, Pamela Surkan.

**Financial support.** This work was supported by National Institutes of Health (NIH) grants to D.G. (DPI DA028994 and R01 DA30985). A.D. was supported in part by NIH T32-AI007386. S.S.M was supported in part by Harvard Catalyst Master's Program in Clinical and Translational Investigation funded by the NIH Clinical and Translational Science Award Program (1UL1-TR001102); biostatistical consultation was provided by the Harvard Center for AIDS Research (P30 AI060354). The MACS is funded by the National Institute of Allergy and Infectious Diseases (U01-AI35039, U01-AI35040; U01-AI35041; U01-AI35042; and UM1-AI35043), with additional cofunding from the National Cancer Institute, National Institute on Drug Abuse, and National Institute of Mental Health at the NIH. MACS data collection is also supported by UL1-TR000424 (Johns Hopkins University NIH Clinical and Translational Science Award).

**Potential conflicts of interest:** All authors: No reported conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

### References

1. Chao C, Jacobson LP, Tashkin D, et al. Recreational drug use and T lymphocyte subpopulations in HIV-uninfected and HIV-infected men. *Drug Alcohol Depend* 2008; 94:165–71.
2. Mimiaga MJ, Reisner SL, Grasso C, et al. Substance use among HIV-infected patients engaged in primary care in the United States: findings from the Centers for AIDS Research Network of Integrated Clinical Systems cohort. *Am J Public Health* 2013; 103:1457–67.
3. Okafor CN, Cook RL, Chen X, et al. Trajectories of marijuana use among HIV-seropositive and HIV-seronegative MSM in the Multicenter AIDS Cohort Study (MACS), 1984–2013. *AIDS Behav* 2017; 21:1091–104.

4. National Academies of Sciences, Engineering, and Medicine. *The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research*. Washington (DC): The National Academies Press, 2017.
5. Abrams DI, Hilton JF, Leiser RJ, et al. Short-term effects of cannabinoids in patients with HIV-1 infection: a randomized, placebo-controlled clinical trial. *Ann Intern Med* 2003; 139:258–66.
6. Di Franco MJ, Sheppard HW, Hunter DJ, Tosteson TD, Ascher MS. The lack of association of marijuana and other recreational drugs with progression to AIDS in the San Francisco Men's Health Study. *Ann Epidemiol* 1996; 6:283–9.
7. Milloy MJ, Marshall B, Kerr T, et al. High-intensity cannabis use associated with lower plasma human immunodeficiency virus-1 RNA viral load among recently infected people who use injection drugs. *Drug Alcohol Rev* 2015; 34:135–40.
8. Okafor CN, Zhou Z, Burrell LE, 2nd, et al. Marijuana use and viral suppression in persons receiving medical care for HIV-infection. *Am J Drug Alcohol Abuse* 2016; 1–8.
9. Thames AD, Mahmood Z, Burggren AC, Karimian A, Kuhn TP. Combined effects of HIV and marijuana use on neurocognitive functioning and immune status. *AIDS Care* 2016; 28:628–32.
10. D'Souza G, Matson PA, Grady CD, et al. Medicinal and recreational marijuana use among HIV-infected women in the Women's Interagency HIV Study (WIHS) cohort, 1994–2010. *J Acquir Immune Defic Syndr* 2012; 61:618–26.
11. Amedee AM, Nichols WA, LeCapitaine NJ, et al. Chronic  $\Delta^9$ -tetrahydrocannabinol administration may not attenuate simian immunodeficiency virus disease progression in female rhesus macaques. *AIDS Res Hum Retroviruses* 2014; 30:1216–25.
12. Molina PE, Amedee AM, LeCapitaine NJ, et al. Modulation of gut-specific mechanisms by chronic  $\delta(9)$ -tetrahydrocannabinol administration in male rhesus macaques infected with simian immunodeficiency virus: a systems biology analysis. *AIDS Res Hum Retroviruses* 2014; 30:567–78.
13. Freiberg MS, So-Armah K. HIV and cardiovascular disease: we need a mechanism, and we need a plan. *J Am Heart Assoc* 2016; 4:e003411.
14. Kaplan RC, Hanna DB, Kizer JR. Recent insights into cardiovascular disease (CVD) risk among HIV-infected adults. *Curr HIV/AIDS Rep* 2016; 13:44–52.
15. Martin-Iguacel R, Llibre JM, Friis-Moller N. Risk of cardiovascular disease in an aging HIV population: where are we now? *Curr HIV/AIDS Rep* 2015; 12:375–87.
16. Bozzette SA, Ake CF, Tam HK, Chang SW, Louis TA. Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. *N Engl J Med* 2003; 348:702–10.
17. Currier JS, Taylor A, Boyd F, et al. Coronary heart disease in HIV-infected individuals. *J Acquir Immune Defic Syndr* 2003; 33:506–12.
18. Freiberg MS, Chang CC, Kuller LH, et al. HIV infection and the risk of acute myocardial infarction. *JAMA Intern Med* 2013; 173:614–22.
19. Kaplan RC, Kingsley LA, Sharrett AR, et al. Ten-year predicted coronary heart disease risk in HIV-infected men and women. *Clin Infect Dis* 2007; 45:1074–81.
20. Kelly SG, Plankey M, Post WS, et al. Associations between tobacco, alcohol, and drug use with coronary artery plaque among HIV-infected and uninfected men in the Multicenter AIDS Cohort Study. *PLoS One* 2016; 11:e0147822.
21. Monroe AK, Haberlen SA, Post WS, et al. Cardiovascular disease risk scores' relationship to subclinical cardiovascular disease among HIV-infected and HIV-uninfected men. *AIDS* 2016; 30:2075–84.
22. Thomas G, Kloner RA, Rezkalla S. Adverse cardiovascular, cerebrovascular, and peripheral vascular effects of marijuana inhalation: what cardiologists need to know. *Am J Cardiol* 2014; 113:187–90.
23. Desbois AC, Cacoub P. Cannabis-associated arterial disease. *Ann Vasc Surg* 2013; 27:996–1005.
24. Jouanjus E, Lapeyre-Mestre M, Micallef J; French Association of the Regional Abuse and Dependence Monitoring Centres (CEIP-A) Working Group on Cannabis Complications. Cannabis use: signal of increasing risk of serious cardiovascular disorders. *J Am Heart Assoc* 2014; 3:e000638.
25. Mittleman MA, Lewis RA, Maclure M, Sherwood JB, Muller JE. Triggering myocardial infarction by marijuana. *Circulation* 2001; 103:2805–9.
26. Detels R, Jacobson L, Margolick J, et al. The multicenter AIDS cohort study, 1983 to.... *Public Health* 2012; 126:196–8.
27. Kaslow RA, Ostrow DG, Detels R, Phair JP, Polk BF, Rinaldo CR Jr. The Multicenter AIDS Cohort Study: rationale, organization, and selected characteristics of the participants. *Am J Epidemiol* 1987; 126:310–8.
28. Friedman GD, Tekawa I, Grimm RH, Manolio T, Shannon SG, Sidney S. The leucocyte count: correlates and relationship to coronary risk factors: the CARDIA study. *Int J Epidemiol* 1990; 19:889–93.
29. Sunyer J, Muñoz A, Peng Y, et al. Longitudinal relation between smoking and white blood cells. *Am J Epidemiol* 1996; 144:734–41.

30. Hessel NA, Kalinowski A, Benning L, et al. Mortality among participants in the Multicenter AIDS Cohort Study and the Women's Interagency HIV Study. *Clin Infect Dis* **2007**; 44:287–94.
31. Seaberg EC, Wiley D, Martinez-Maza O, et al. Cancer incidence in the Multicenter AIDS Cohort Study before and during the HAART era: 1984 to 2007. *Cancer* **2010**; 116:5507–16.
32. Madjid M, Awan I, Willerson JT, Casscells SW. Leukocyte count and coronary heart disease: implications for risk assessment. *J Am Coll Cardiol* **2004**; 44:1945–56.
33. Twig G, Afek A, Shamiss A, et al. White blood cell count and the risk for coronary artery disease in young adults. *PLoS One* **2012**; 7:e47183.
34. Hall W, Weier M. Assessing the public health impacts of legalizing recreational cannabis use in the USA. *Clin Pharmacol Ther* **2015**; 97:607–15.
35. Meier MH, Caspi A, Cerdá M, et al. Associations between cannabis use and physical health problems in early midlife: a longitudinal comparison of persistent cannabis vs tobacco users. *JAMA Psychiatry* **2016**; 73:731–40.
36. Volkow ND, Compton WM, Weiss SR. Adverse health effects of marijuana use. *N Engl J Med* **2014**; 371:879.
37. Post WS, Budoff M, Kingsley L, et al. Associations between HIV infection and subclinical coronary atherosclerosis. *Ann Intern Med* **2014**; 160:458–67.
38. Wei B, Alwis KU, Li Z, et al. Urinary concentrations of PAH and VOC metabolites in marijuana users. *Environ Int* **2016**; 88:1–8.
39. Marcellin F, Lions C, Rosenthal E, et al; HEPAVIH ANRS CO13 Study Group. No significant effect of cannabis use on the count and percentage of circulating CD4 T-cells in HIV-HCV co-infected patients (ANRS CO13-HEPAVIH French cohort). *Drug Alcohol Rev* **2017**; 36:227–38.
40. Akhtar-Khaleel WZ, Cook RL, Shoptaw S, et al. Long-term cigarette smoking trajectories among HIV-seropositive and seronegative MSM in the Multicenter AIDS Cohort Study. *AIDS Behav* **2016**; 20:1713–21.